Status:
COMPLETED
A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30+ years
Phase:
PHASE3
Brief Summary
This study is not being conducted in the United States. The purpose of this study is to assess the effect of vildagliptin, an unapproved drug, on various measures of pancreatic islet function in peopl...
Eligibility Criteria
Inclusion
- Not currently on drug therapy for type 2 diabetes
- Blood glucose criteria must be met
Exclusion
- History of type 1 diabetes
- Evidence of significant diabetic complications
- Serious cardiovascular events within the past 6 months
- Other protocol-defined exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT00260156
Start Date
November 1 2005
End Date
December 1 2008
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Basel, Switzerland